These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18544593)

  • 1. Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France.
    Elalamy I; Le Gal G; Nachit-Ouinekh F; Lafuma A; Emery C; Le-Fur C; Chapuis F
    Clin Appl Thromb Hemost; 2009; 15(4):428-34. PubMed ID: 18544593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes.
    Baroletti S; Piovella C; Fanikos J; Labreche M; Lin J; Goldhaber SZ
    Thromb Haemost; 2008 Dec; 100(6):1130-5. PubMed ID: 19132240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution].
    Couffignal AL; Lapeyre-Mestre M; Bonhomme C; Bugat R; Montastruc JL
    Therapie; 2000; 55(5):635-41. PubMed ID: 11201979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions.
    Subahi A; Osman M; Adegbala O; Abubakar H; Kheiri B; Yassin AS; Khalid M; Akintoye E; Eljack A; Osman K; Alkhouli M
    Vascular; 2020 Feb; 28(1):81-86. PubMed ID: 31382836
    [No Abstract]   [Full Text] [Related]  

  • 6. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital.
    Lugardon S; Desboeuf K; Fernet P; Montastruc JL; Lapeyre-Mestre M
    Br J Clin Pharmacol; 2006 Aug; 62(2):225-31. PubMed ID: 16842398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database.
    Hauptman PJ; Swindle J; Burroughs TE; Schnitzler MA
    Am Heart J; 2008 Jun; 155(6):978-985.e1. PubMed ID: 18513507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital utilization and costs among children with influenza, 2003.
    Hassan F; Lewis TC; Davis MM; Gebremariam A; Dombkowski K
    Am J Prev Med; 2009 Apr; 36(4):292-6. PubMed ID: 19201147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).
    Lopes RD; Ohman EM; Granger CB; Honeycutt EF; Anstrom KJ; Berger PB; Crespo EM; Oliveira GB; Moll S; Moliterno DJ; Abrams CS; Becker RC
    Am J Cardiol; 2009 Nov; 104(9):1285-91. PubMed ID: 19840578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
    Crespo EM; Oliveira GB; Honeycutt EF; Becker RC; Berger PB; Moliterno DJ; Anstrom KJ; Abrams CS; Kleiman NS; Moll S; Rice L; Rodgers JE; Steinhubl SR; Tapson VF; Granger CB; Ohman EM;
    Am Heart J; 2009 Apr; 157(4):651-7. PubMed ID: 19332191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National trends and determinants of hospitalization costs and lengths-of-stay for uterine fibroids procedures.
    Becker ER
    J Health Care Finance; 2007; 33(3):1-16. PubMed ID: 19175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of dengue in three French territories of the Americas: an analysis of the hospital medical information system (PMSI) database.
    Uhart M; Blein C; L'Azou M; Thomas L; Durand L
    Eur J Health Econ; 2016 May; 17(4):497-503. PubMed ID: 25962729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic consequences of biological monitoring and medical complications of injectable anticoagulants in France].
    Paubel P; Cousin M; Amar C; Gourmelen J; Fabron C; Detournay B
    J Mal Vasc; 2016 Dec; 41(6):371-377. PubMed ID: 27817998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura.
    Danese MD; Lindquist K; Gleeson M; Deuson R; Mikhael J
    Am J Hematol; 2009 Oct; 84(10):631-5. PubMed ID: 19705429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism.
    Stein PD; Hull RD; Matta F; Yaekoub AY; Liang J
    Am J Med; 2009 Oct; 122(10):919-30. PubMed ID: 19682670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
    Chevalier J; Bonastre J; Avril MF
    Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Length of stay and costs for asthma patients by hospital characteristics--a five-year population-based analysis.
    Lin HC; Kao S; Wen HC; Wu CS; Chung CL
    J Asthma; 2005 Sep; 42(7):537-42. PubMed ID: 16169785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis.
    Gainza FJ; Quintanilla N; Pijoan JI; Delgado S; Urbizu JM; Lampreabe I
    J Nephrol; 2006; 19(5):648-55. PubMed ID: 17136695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.